Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR.

Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Inclusion Criteria:

• Normal kidney function, liver function and hemoglobin levels.

Exclusion Criteria:

• Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2